TY - JOUR T1 - Syncope at SARS-CoV-2 onset due to impaired baroreflex response JF - medRxiv DO - 10.1101/2020.05.29.20114751 SP - 2020.05.29.20114751 AU - Ciro Canetta AU - Silvia Accordino AU - Elisabetta Buscarini AU - Gianpaolo Benelli AU - Giuseppe La Piana AU - Alessandro Scartabellati AU - Giovanni ViganĂ² AU - Roberto Assandri AU - Alberto Astengo AU - Chiara Benzoni AU - Gianfranco Gaudiano AU - Daniele Cazzato AU - Davide Sebastiano Rossi AU - Susanna Usai AU - Irene Tramacere AU - Giuseppe Lauria Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.29.20114751.abstract N2 - We describe clinical and laboratory findings in 35 consecutive patients tested positive for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction on nasopharyngeal swab that presented one or multiple syncopal events at disease onset. Neurological examination and electrocardiographic findings were normal. Chest computed tomography showed findings consistent with interstitial pneumonia. Arterial blood gas analysis showed low pO2, pCO2, and P/F ratio indicating hypocapnic hypoxemia, while patients did not show the expected compensatory heart rate increase. Such mechanism could have led to syncope. We speculate that SARS-CoV-2 could have caused angiotensin-converting enzyme-2 (ACE2) receptor internalization in the nucleus of the solitary tract (NTS), thus altering the baroreflex response and inhibiting the compensatory tachycardia during acute hypocapnic hypoxemia.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the Hospital of Crema has approved the study. All the experiment protocol for involving human data was accordance to guidelines of national/international/institutional or Declaration of Helsinki in the manuscript. Written informed consent was obtained from all participants and legally authorized representatives of minors below 18 patients and dead patientsgave consent for data that could be used for clinical studiesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSee Availability statement ER -